CDCD27: A Potential Drug Target for Cancer and Inflammation (G148870)

Target Name: CCDC27

NCBI ID: G148870

CCDC27

CDCD27: A Potential Drug Target for Cancer and Inflammation

CCDC27, also known as CCD27, is a protein that is expressed in various tissues throughout the body, including the skin, lungs, and gastrointestinal tract. It is a member of the immunoglobulin superfamily and is involved in the development and maintenance of immune responses. CCDC27 has also been shown to play a role in cancer progression and has potential as a drug target or biomarker.

CDC27 is a transmembrane protein that is expressed in the cytoplasm of various cell types. It consists of an extracellular domain that is involved in cell adhesion and interaction, a transmembrane domain that spans the entire cell membrane, and an intracellular domain that is involved in protein -protein interactions and signaling. The extracellular domain of CCDC27 contains a variety of cytoplasmic structures, including a long N-terminus that is involved in cell adhesion and a short C-terminus that is involved in interaction with other proteins.

CDC27 is involved in the development and maintenance of immune responses, including the regulation of T cell proliferation and the development of cancer. Research shows that CCDC27 plays a role in the regulation of T cell receptor (TCR) signaling, which is critical for the development of T cell-mediated immunity against viruses and cancer.

In addition to its role in T cell biology, CCDC27 has also been shown to be involved in the regulation of inflammation and immune cell function. Research has shown that CCDC27 is involved in the regulation of the production and function of immune cells, including natural killer cells , T cells, and B cells. It is also involved in the regulation of inflammation, including the regulation of cytokine production and the recruitment of immune cells to sites of infection or injury.

CDC27 has also been shown to be involved in the regulation of cell survival and apoptosis. Research has shown that CCDC27 is involved in the regulation of cell survival and apoptosis, including the regulation of cell cycle progression and the inhibition of apoptosis. This may be important for the regulation of cellular processes that are critical for the development and maintenance of tissues and organs.

CDC27 has potential as a drug target or biomarker due to its involvement in various biological processes that are important for human health. For example, CCDC27 has been shown to be involved in the regulation of T cell biology, which is critical for the development and maintenance of T cell-mediated immunity against viruses and cancer. Therefore, compounds that can modulate CCDC27 activity may be useful for the development of cancer therapies. Additionally, CCDC27 has been shown to be involved in the regulation of inflammation and immune cell function, which may be important for the regulation of cellular processes that are critical for the development and maintenance of tissues and organs. Therefore, compounds that can modulate CCDC27 activity may be useful for the development of therapies for inflammation and autoimmune diseases.

In conclusion, CCDC27 is a protein that is involved in the development and maintenance of immune responses and has potential as a drug target or biomarker. Its involvement in T cell biology, inflammation, and cell survival and apoptosis makes it an attractive target for the development of therapies for cancer, inflammation, and autoimmune diseases. Further research is needed to fully understand the role of CCDC27 in these processes and to develop compounds that can modulate its activity.

Protein Name: Coiled-coil Domain Containing 27

The "CCDC27 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC27 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets